New drug IMM2510 plus chemo for first-line lung or breast cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (IMM2510) combined with chemotherapy as a first treatment for people with either non-small cell lung cancer or triple-negative breast cancer. It looks at how safe and effective the combination is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have either non-small cell lung cancer (NSCLC) that is EGFR wild-type and ALK/ROS1 negative, or triple-negative breast cancer (TNBC).
- You have not received any previous treatment for advanced cancer, or if you had earlier treatment, it ended more than 12 months ago.
- You are able to provide a tumor tissue sample (from a past biopsy or a new one) for testing.
- You have measurable tumors (visible on scans) and can care for yourself (ECOG score 0 or 1).
- You agree to use effective contraception during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a new drug combined with chemotherapy compared to a standard immunotherapy combined with chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the new combination is more effective and may offer a new first-line treatment option.
This trial tests a new investigational drug combined with chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. The goal is to see if it is safe and works better than current treatments.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests a new drug called HB0025 combined with chemotherapy for people with advanced non-squamous non-small cell lung cancer who haven't had treatment before. It compares this combination to the current standard treatment (tislelizumab plus chemo) to see which works better.
This trial tests a new drug (RC148) plus chemotherapy against another drug (Tislelizumab) plus chemotherapy for people with a type of lung cancer called squamous non-small cell lung cancer that has spread or can't be removed. It's for those who haven't had treatment for advanced disease yet.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.